Announcement • May 20
Titan Biotech Limited to Report Fiscal Year 2026 Results on May 30, 2026 Titan Biotech Limited announced that they will report fiscal year 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026 Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₹410, the stock trades at a trailing P/E ratio of 62.3x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 775% over the past three years. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹458, the stock trades at a trailing P/E ratio of 69.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 1,008% over the past three years. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹276, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 556% over the past three years. New Risk • Feb 19
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹2.15b market cap, or US$23.6m). New Risk • Feb 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.0% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Reported Earnings • Feb 14
Third quarter 2026 earnings released: EPS: ₹10.32 (vs ₹5.31 in 3Q 2025) Third quarter 2026 results: EPS: ₹10.32 (up from ₹5.31 in 3Q 2025). Revenue: ₹577.6m (up 51% from 3Q 2025). Net income: ₹85.3m (up 94% from 3Q 2025). Profit margin: 15% (up from 12% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 74% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 13
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹1,212, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 437% over the past three years. Announcement • Feb 03
Titan Biotech Limited to Report Q3, 2026 Results on Feb 12, 2026 Titan Biotech Limited announced that they will report Q3, 2026 results on Feb 12, 2026 Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,088, the stock trades at a trailing P/E ratio of 39x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 255% over the past three years. Announcement • Nov 04
Titan Biotech Limited to Report Q2, 2026 Results on Nov 11, 2025 Titan Biotech Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Nov 11, 2025 Valuation Update With 7 Day Price Move • Oct 09
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹1,131, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 330% over the past three years. Valuation Update With 7 Day Price Move • Sep 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹781, the stock trades at a trailing P/E ratio of 29.3x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 183% over the past three years. Upcoming Dividend • Sep 12
Upcoming dividend of ₹2.00 per share Eligible shareholders must have bought the stock before 19 September 2025. Payment date: 26 October 2025. Payout ratio is a comfortable 7.7% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%). New Risk • Aug 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.7% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (₹3.86b market cap, or US$44.0m). Valuation Update With 7 Day Price Move • Aug 26
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹547, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 123% over the past three years. Declared Dividend • Aug 15
Dividend of ₹2.00 announced Dividend of ₹2.00 is the same as last year. Ex-date: 19th September 2025 Payment date: 26th October 2025 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (8% earnings payout ratio) and cash flows (15% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 4.3% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Aug 14
Titan Biotech Limited, Annual General Meeting, Sep 26, 2025 Titan Biotech Limited, Annual General Meeting, Sep 26, 2025, at 15:00 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2026 earnings released: EPS: ₹8.30 (vs ₹7.74 in 1Q 2025) First quarter 2026 results: EPS: ₹8.30 (up from ₹7.74 in 1Q 2025). Revenue: ₹472.2m (up 9.5% from 1Q 2025). Net income: ₹68.6m (up 7.2% from 1Q 2025). Profit margin: 14% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Announcement • Aug 02
Titan Biotech Limited to Report Q1, 2026 Results on Aug 13, 2025 Titan Biotech Limited announced that they will report Q1, 2026 results on Aug 13, 2025 Reported Earnings • May 31
Full year 2025 earnings released: EPS: ₹26.06 (vs ₹30.08 in FY 2024) Full year 2025 results: EPS: ₹26.06 (down from ₹30.08 in FY 2024). Revenue: ₹1.60b (down 2.3% from FY 2024). Net income: ₹215.3m (down 13% from FY 2024). Profit margin: 13% (down from 15% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Announcement • May 26
Titan Biotech Limited to Report Q4, 2025 Results on May 30, 2025 Titan Biotech Limited announced that they will report Q4, 2025 results on May 30, 2025 Reported Earnings • Feb 14
Third quarter 2025 earnings released: EPS: ₹5.31 (vs ₹8.68 in 3Q 2024) Third quarter 2025 results: EPS: ₹5.31 (down from ₹8.68 in 3Q 2024). Revenue: ₹398.7m (down 13% from 3Q 2024). Net income: ₹43.9m (down 39% from 3Q 2024). Profit margin: 11% (down from 16% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 13
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to ₹543, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 105% over the past three years. Announcement • Feb 03
Titan Biotech Limited to Report Q3, 2025 Results on Feb 12, 2025 Titan Biotech Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Reported Earnings • Nov 13
Second quarter 2025 earnings released: EPS: ₹8.10 (vs ₹7.89 in 2Q 2024) Second quarter 2025 results: EPS: ₹8.10 (up from ₹7.89 in 2Q 2024). Revenue: ₹402.1m (down 7.4% from 2Q 2024). Net income: ₹67.0m (up 2.7% from 2Q 2024). Profit margin: 17% (up from 15% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 44% per year, which means it is well ahead of earnings. Announcement • Nov 06
Titan Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024 Titan Biotech Limited announced that they will report Q2, 2025 results on Nov 12, 2024 Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹920, the stock trades at a trailing P/E ratio of 30.3x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 196% over the past three years. Upcoming Dividend • Sep 19
Upcoming dividend of ₹2.00 per share Eligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 6.7% and the cash payout ratio is 92%. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%). Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹722, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 112% over the past three years. Declared Dividend • Sep 05
Dividend increased to ₹2.00 Dividend of ₹2.00 is 11% higher than last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (14% cash payout ratio). The dividend has increased by an average of 10% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 41% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Sep 04
Titan Biotech Limited, Annual General Meeting, Sep 30, 2024 Titan Biotech Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2025 earnings released: EPS: ₹7.74 (vs ₹7.47 in 1Q 2024) First quarter 2025 results: EPS: ₹7.74 (up from ₹7.47 in 1Q 2024). Revenue: ₹431.1m (up 24% from 1Q 2024). Net income: ₹64.0m (up 3.9% from 1Q 2024). Profit margin: 15% (down from 18% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Announcement • Aug 04
Titan Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024 Titan Biotech Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹30.07 (vs ₹30.06 in FY 2023) Full year 2024 results: EPS: ₹30.07 (up from ₹30.06 in FY 2023). Revenue: ₹1.64b (up 14% from FY 2023). Net income: ₹248.5m (flat on FY 2023). Profit margin: 15% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Announcement • May 30
Titan Biotech Limited Recommends Dividend for the Financial Year Ended on 31 March, 2024 Titan Biotech Limited have recommended a dividend of INR 2.00/- per equity share for the Financial Year ended on 31st March, 2024. The said dividend, if declared at the upcoming Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws. Valuation Update With 7 Day Price Move • May 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹597, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 100% over the past three years. Announcement • May 20
Titan Biotech Limited to Report Q4, 2024 Results on May 29, 2024 Titan Biotech Limited announced that they will report Q4, 2024 results on May 29, 2024 Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹594, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 249% over the past three years. Reported Earnings • Feb 13
Third quarter 2024 earnings released: EPS: ₹8.68 (vs ₹3.95 in 3Q 2023) Third quarter 2024 results: EPS: ₹8.68 (up from ₹3.95 in 3Q 2023). Revenue: ₹464.2m (up 53% from 3Q 2023). Net income: ₹71.7m (up 120% from 3Q 2023). Profit margin: 16% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings. New Risk • Feb 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹3.83b market cap, or US$46.2m). Announcement • Feb 01
Titan Biotech Limited to Report Q3, 2024 Results on Feb 12, 2024 Titan Biotech Limited announced that they will report Q3, 2024 results on Feb 12, 2024 Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹502, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 200% over the past three years. Reported Earnings • Nov 10
Second quarter 2024 earnings released: EPS: ₹7.89 (vs ₹11.04 in 2Q 2023) Second quarter 2024 results: EPS: ₹7.89 (down from ₹11.04 in 2Q 2023). Revenue: ₹439.8m (up 5.1% from 2Q 2023). Net income: ₹65.2m (down 28% from 2Q 2023). Profit margin: 15% (down from 22% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 40% per year, which means it is well ahead of earnings. Upcoming Dividend • Sep 15
Upcoming dividend of ₹1.80 per share at 0.5% yield Eligible shareholders must have bought the stock before 22 September 2023. Payment date: 29 October 2023. Payout ratio is a comfortable 6.0% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%). Reported Earnings • Sep 06
Full year 2023 earnings released: EPS: ₹25.44 (vs ₹30.66 in FY 2022) Full year 2023 results: EPS: ₹25.44 (down from ₹30.66 in FY 2022). Revenue: ₹1.46b (down 4.6% from FY 2022). Net income: ₹248.4m (down 1.9% from FY 2022). Profit margin: 17% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 02
Titan Biotech Limited, Annual General Meeting, Sep 29, 2023 Titan Biotech Limited, Annual General Meeting, Sep 29, 2023, at 15:00 Indian Standard Time. New Risk • Aug 07
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹2.76b market cap, or US$33.3m). Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₹334, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 228% over the past three years. Announcement • Aug 01
Titan Biotech Limited to Report Q1, 2024 Results on Aug 10, 2023 Titan Biotech Limited announced that they will report Q1, 2024 results on Aug 10, 2023 Announcement • Jul 27
Titan Biotech Limited Announces Resignation of Rekha Dalmia as Non-Executive Independent Director Titan Biotech Limited announced that Mrs. Rekha Dalmia has resigned from directorship (In capacity of non-executive independent director) of the company with effect from 25 July 2023, due to pre-occupation and other personal commitments. Consequently, she shall also cease to be Chairman/Member of Nomination and remuneration committee, Corporate Social Responsibility Committee and Audit Committee of the Company. Announcement • May 31
Titan Biotech Limited Recommends Dividend for the Financial Year Ended on March 31, 2023 Titan Biotech Limited announced that at the board meeting held on May 29, 2023, the company recommended of a dividend of INR 1.80/- (One Rupees Eighty Paisa Only) per equity share for the Financial Year ended on March 31, 2023. Announcement • May 17
Titan Biotech Limited to Report Q4, 2023 Results on May 29, 2023 Titan Biotech Limited announced that they will report Q4, 2023 results on May 29, 2023 Reported Earnings • Feb 05
Third quarter 2023 earnings released: EPS: ₹3.95 (vs ₹6.33 in 3Q 2022) Third quarter 2023 results: EPS: ₹3.95 (down from ₹6.33 in 3Q 2022). Revenue: ₹306.1m (down 15% from 3Q 2022). Net income: ₹32.6m (down 38% from 3Q 2022). Profit margin: 11% (down from 14% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 27
Titan Biotech Limited to Report Q3, 2023 Results on Feb 04, 2023 Titan Biotech Limited announced that they will report Q3, 2023 results on Feb 04, 2023 Reported Earnings • Nov 19
Second quarter 2023 earnings released: EPS: ₹11.04 (vs ₹7.74 in 2Q 2022) Second quarter 2023 results: EPS: ₹11.04 (up from ₹7.74 in 2Q 2022). Revenue: ₹426.9m (up 4.5% from 2Q 2022). Net income: ₹91.3m (up 43% from 2Q 2022). Profit margin: 21% (up from 16% in 2Q 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Non-Executive Independent Director Rohit Jain was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buying Opportunity • Nov 11
Now 21% undervalued Over the last 90 days, the stock is up 22%. The fair value is estimated to be ₹360, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 54%. Announcement • Nov 05
Titan Biotech Limited to Report Q2, 2023 Results on Nov 14, 2022 Titan Biotech Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Announcement • Oct 02
Titan Biotech Limited Appoints Raja Singla as Executive Director, with Effect from October 1, 2022 Titan Biotech Limited approved the appointment of Mr. Raja Singla (DIN: 03523719) in the category of Executive Director of the Company for a term of 5 (five) years with effect from October 1, 2022. Currently, Mr. Raja Singla is associated with Company as a Senior Vice President- Production of the Company from 01 October, 2019. Experience in Production of over 8 years in Phoenix Bio Sciences Private Limited and over 2.5 years in Titan Biotech Limited.Mr. Naresh Kumar Singla, Managing Director is Father of appointee Director. Upcoming Dividend • Sep 15
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 22 September 2022. Payment date: 30 October 2022. Payout ratio is a comfortable 4.9% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%). Reported Earnings • Sep 02
Full year 2022 earnings released: EPS: ₹30.66 (vs ₹36.71 in FY 2021) Full year 2022 results: EPS: ₹30.66 (down from ₹36.71 in FY 2021). Revenue: ₹1.54b (up 8.1% from FY 2021). Net income: ₹253.3m (down 17% from FY 2021). Profit margin: 17% (down from 21% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has increased by 103% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 27
Titan Biotech Limited, Annual General Meeting, Sep 30, 2022 Titan Biotech Limited, Annual General Meeting, Sep 30, 2022, at 15:00 Indian Standard Time. Announcement • May 31
Titan Biotech Limited Recommends Dividend for the Financial Year Ended on 31 March, 2022 The Board of Directors of Titan Biotech Limited have recommended a dividend of INR 1.50/- (Rupees One Fifty Paisa Only) per equity share for the Financial Year ended on 31 March, 2022. The said dividend, if declared at the ensuing Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Rohit Jain was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹226, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 387% over the past three years. Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹6.33 (down from ₹8.02 in 3Q 2021). Revenue: ₹359.7m (up 4.0% from 3Q 2021). Net income: ₹52.3m (down 21% from 3Q 2021). Profit margin: 14% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 78% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹260, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 405% over the past three years. Upcoming Dividend • Sep 09
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 16 September 2021. Payment date: 24 October 2021. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%). Executive Departure • Aug 18
Independent Non Executive Chairman Jai Bansal has left the company On the 10th of August, Jai Bansal's tenure as Independent Non Executive Chairman ended after 2.4 years in the role. We don't have any record of a personal shareholding under Jai's name. Jai is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.33 years. Reported Earnings • Aug 12
First quarter 2022 earnings released: EPS ₹10.56 (vs ₹15.42 in 1Q 2021) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: ₹415.8m (up 5.5% from 1Q 2021). Net income: ₹87.2m (down 32% from 1Q 2021). Profit margin: 21% (down from 32% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment improved over the past week After last week's 15% share price gain to ₹396, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 635% over the past three years. Reported Earnings • Jul 04
Full year 2021 earnings released: EPS ₹36.71 (vs ₹8.55 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹1.42b (up 79% from FY 2020). Net income: ₹303.4m (up 329% from FY 2020). Profit margin: 21% (up from 8.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year whereas the company’s share price has increased by 83% per year. Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improved over the past week After last week's 16% share price gain to ₹349, the stock trades at a trailing P/E ratio of 10.1x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 551% over the past three years. Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improved over the past week After last week's 34% share price gain to ₹284, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 364% over the past three years. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment improved over the past week After last week's 18% share price gain to ₹202, the stock is trading at a trailing P/E ratio of 5.9x, up from the previous P/E ratio of 5x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 221%. Is New 90 Day High Low • Mar 08
New 90-day high: ₹202 The company is up 43% from its price of ₹142 on 08 December 2020. The Indian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improved over the past week After last week's 18% share price gain to ₹201, the stock is trading at a trailing P/E ratio of 5.8x, up from the previous P/E ratio of 4.9x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 191%. Is New 90 Day High Low • Feb 11
New 90-day high: ₹192 The company is up 44% from its price of ₹133 on 13 November 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. Reported Earnings • Jan 30
Third quarter 2021 earnings released: EPS ₹8.02 (vs ₹2.13 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹346.0m (up 84% from 3Q 2020). Net income: ₹66.2m (up 276% from 3Q 2020). Profit margin: 19% (up from 9.4% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Announcement • Jan 19
Titan Biotech Limited to Report Q3, 2021 Results on Jan 27, 2021 Titan Biotech Limited announced that they will report Q3, 2021 results on Jan 27, 2021 Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 23% share price gain to ₹180, the stock is trading at a trailing P/E ratio of 6.3x, up from the previous P/E ratio of 5.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 170%. Valuation Update With 7 Day Price Move • Dec 14
Investor sentiment improved over the past week After last week's 18% share price gain to ₹152, the stock is trading at a trailing P/E ratio of 5.3x, up from the previous P/E ratio of 4.5x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 158%. Is New 90 Day High Low • Nov 10
New 90-day low: ₹126 The company is down 4.0% from its price of ₹131 on 12 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. Valuation Update With 7 Day Price Move • Oct 26
Market pulls back on stock over the past week After last week's 22% share price decline to ₹147, the stock is trading at a trailing P/E ratio of 5.1x, down from the previous P/E ratio of 6.5x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 141%. Reported Earnings • Oct 21
First half earnings released Over the last 12 months the company has reported total profits of ₹236.3m, up 377% from the prior year. Total revenue was ₹1.11b over the last 12 months, up 52% from the prior year. Is New 90 Day High Low • Oct 16
New 90-day high: ₹185 The company is up 130% from its price of ₹80.50 on 17 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. Valuation Update With 7 Day Price Move • Oct 13
Market bids up stock over the past week After last week's 16% share price gain to ₹171, the stock is trading at a trailing P/E ratio of 7.9x, up from the previous P/E ratio of 6.9x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 179%. Announcement • Oct 10
Titan Biotech Limited to Report Q2, 2020 Results on Oct 19, 2020 Titan Biotech Limited announced that they will report Q2, 2020 results on Oct 19, 2020 Announcement • Jun 20
Titan Biotech Limited to Report Fiscal Year 2020 Results on Jun 30, 2020 Titan Biotech Limited announced that they will report fiscal year 2020 results on Jun 30, 2020